Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The present study is designed to evaluate the modulatory effect of IP on the vascular endothelial function. To assess its vasodilatation potential, change in flow mediated dilation (FMD) and blood flow velocity (BFV) will be assessed in healthy adult male population.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Moringa oleifera (E-HS-01) | Active Comparator | One capsule to be taken stat |
|
| Placebo | Placebo Comparator | One capsule to be taken stat |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Moringa oleifera (E-HS-01) | Other | One capsule to be taken stat |
|
| Measure | Description | Time Frame |
|---|---|---|
| Percent flow mediated dilatation | To determine change in the endothelial function after single dose administration of Moringa oleifera as assessed by the change in the Percent flow mediated dilatation of brachial artery, from baseline (pre-IP administration) to 3 hours post IP administration, in comparison to the placebo. | From baseline (pre-IP administration) to 3 hours post-IP administration |
| Measure | Description | Time Frame |
|---|---|---|
| Blood flow velocity | The endothelial function can be assessed by measuring changes in blood flow by intravascular ultrasound. It has been demonstrated that biophysical forces such as flow-derived forces, modulates the vascular structure and function. Endothelium is mechanotransducer, which senses mechanical forces on its surface and the transduces these signals into biochemical signals. There exists a large body of literature regarding the wide spectra of biological signals induced by blood flow in the endothelium.18 Thus to evaluate the effect of Moringa oleifera on hemodynamics, change in blood flow velocity (cm/seconds) will be assessed at baseline (pre-IP administration) and at 1, 2, and 3 hours post-IP administration will be measured. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Participants with history of pulmonary disorders (asthma, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, pneumonia, etc)
Participants having fasting blood glucose (FBG) levels ≥ 125 mg/dL.
Participants currently on/or having history of taking antihypertensives / diuretics.
Smokers and tobacco users.
Participants with heavy alcohol consumption, defined as more than 14 standard alcoholic drink (SAD)/week or more than 4 SAD in a day.
(NOTE - A standard alcoholic drink contains approximately 14 grams of alcohol, which is equivalent to 12 ounces of beer (~5% alcohol), 8.5 ounces of malt liquor (~9% alcohol), 5 ounces of wine (~12% alcohol), 3.5 ounces of fortified wine (e.g., sherry or port), or 1.5 ounces of liquor (distilled spirits; ~40% alcohol).
Participants currently on performance enhancing supplements.
History/symptoms of coronary artery disease, myocardial infarction etc.
Participants with any other condition which in the view of the investigator is likely to interfere with the study or put the participants at risk.
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Dr. Shalini Dr. Srivastava, MD - Medicine | Contact | 022 42172326 | 326 | shalini.s@vediclifesciences.com |
| Mr. Zubair Ansari, M pharm | Contact | 7738945639 | zubair@vediclifesciences.com |
| Name | Affiliation | Role |
|---|---|---|
| Dr, Anjali Jain, BHMS | Vedic lifesciences | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Vedic Lifesciences | Recruiting | Mumbai | Maharashtra | 400053 | India |
Not provided
Randomized, Double-blind, Cross-over, Placebo controlled study
Not provided
Not provided
Double-blind, Cross-over
| Placebo | Other | One capsule to be taken stat |
|
| at baseline (pre-IP administration) and at 1, 2, and 3 hours post-IP administration |
| Percent flow mediated dilatation | To identify the onset of effect of the investigational product, the flow mediated dilation at 1, and 2 hours post-IP administration from baseline (pre-IP administration) will be assessed as a secondary outcome. | at 1, and 2 hours post-IP administration from baseline (pre-IP administration) |